In a report released today, Matthew O’Brien from Piper Sandler maintained a Buy rating on Tandem Diabetes Care (TNDM – Research Report), with a price target of $50.00. The company’s shares closed yesterday at $36.56.
O’Brien covers the Healthcare sector, focusing on stocks such as Dexcom, Boston Scientific, and Conmed. According to TipRanks, O’Brien has an average return of 6.2% and a 52.25% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tandem Diabetes Care with a $41.55 average price target, a 13.65% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $45.00 price target.
Based on Tandem Diabetes Care’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $196.8 million and a GAAP net loss of $30 million. In comparison, last year the company earned a revenue of $220.5 million and had a GAAP net loss of $15.85 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care (TNDM) Company Description:
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
- Wells upgrades Tandem Diabetes on positive endocrinologist survey
- Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
- Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
- Tandem Diabetes upgraded to Outperform from Market Perform at Leerink
- Tandem Diabetes price target raised to $40 from $37 at Stifel
